Progression-free and overall survival data from Companion-002 are due this quarter.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
The company advances the IDRx-originated KIT inhibitor GSK6042981 into pivotal trials.
Redemption of sorts comes for IO Biotech, but there’s no respite for Summit.
But Perspective sinks again.
The company will acquire ImCheck for €350m.
Innovent’s perseverance with a cytokine approach is rewarded with $1.2bn from Takeda.
Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.
